MycoLogics, Inc. Continues to Expand Antifungal Intellectual Property Portfolio
MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines, today announced the receipt of patent 6,716,625, awarded by the U.S. Patent and Trademark Office, for the discovery of compositions and methods related to fungal histidine kinases and their use in screening compounds for antifungal activity, in addition to the development of antifungal compounds.
DENVER, CO (PRWEB) June 26, 2004 -- MycoLogics, Inc., an innovative
biotechnology company specializing in the development of novel antifungal drugs
and therapeutic and prophylactic vaccines, today announced the receipt of patent
6,716,625, awarded by the U.S. Patent and Trademark Office, for the discovery of
compositions and methods related to fungal histidine kinases and their use in
screening compounds for antifungal activity, in addition to the development of
antifungal compounds.
The present invention provides for the
identification and development of antifungal compounds, as well as the treatment
of subjects to eradicate, mitigate or prevent fungal infections. In particular,
the patent provides for amino acid and nucleotide sequences of fungal histidine
kinases from pathogenic fungi such as Candida, and Aspergillus.
Despite
the identification of the cell membrane, cell wall, and microtubule targets for
antifungal action, antifungal development has been slow. The development of
effective antifungal agents has lagged behind that of antibacterial agents thus,
most agents toxic to fungi are also toxic to humans. MycoLogics, Inc. is
committed to filling the critical and immediate need for new antifungals with
mechanisms of action different from currently available
technologies.
“The Company is very excited about this technology and we
look forward to developing novel antifungals that specifically target fungal
histidine kinases,” said Dr. Claude P. Selitrennikoff, Ph.D., President and
Chief Executive Officer of MycoLogics, Inc.
About MycoLogics,
Inc.:
MycoLogics, Inc. is an innovative biotechnology company specializing in
the development of novel antifungal drugs and therapeutic and prophylactic
vaccines against human fungal and parasitic pathogens, the discovery and
isolation of novel antifungal compounds for therapeutic use, and the development
of novel high throughput assays that target components of fungal cell walls.
MycoLogics, Inc. is headquartered in Aurora, CO at the Fitzsimmons Colorado
Bioscience Park. For more information please visit www.mycologics.com.
CONTACT INFORMATION:
Dr. Claude
P. Selitrennikoff, Ph.D.
President and CEO
MycoLogics, Inc.
Colorado
Bioscience Park
12635 East Montview Blvd., Suite 131
Aurora, CO
80010
Tel: (303) 724-1250
Fax: (303) 724-0861
e-mail protected from
spam bots
# # #
Source : http://www.prweb.com/releases/2004/6/prweb136727.htm